Get the Stockscreener App
40.65
1.37%
0.55
Artivion Inc stock is traded at $40.65, with a volume of 779.66K.
It is up +1.37% in the last 24 hours and down -5.22% over the past month.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
See More
Previous Close:
$40.10
Open:
$40.14
24h Volume:
779.66K
Relative Volume:
2.25
Market Cap:
$1.93B
Revenue:
$405.04M
Net Income/Loss:
$-17.90M
P/E Ratio:
-94.60
EPS:
-0.4297
Net Cash Flow:
$7.66M
1W Performance:
+3.02%
1M Performance:
-5.22%
6M Performance:
-7.30%
1Y Performance:
+36.18%
1-Day Range:
$39.55
$40.93
1-Week Range:
$39.08
$41.00
52-Week Range:
$21.97
$48.25
Artivion Inc Stock (AORT) Company Profile
Name
Artivion Inc
Sector
Industry
Phone
(770) 419-3355
Address
1655 ROBERTS BOULEVARD N W, KENNESAW
Compare AORT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AORT
Artivion Inc
|
40.65 | 1.90B | 405.04M | -17.90M | 7.66M | -0.4297 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Artivion Inc Stock (AORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-17-25 | Initiated | Canaccord Genuity | Buy |
| Oct-23-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-22 | Reiterated | Lake Street | Buy |
| Aug-08-22 | Initiated | Lake Street | Buy |
| Mar-03-22 | Initiated | Stifel | Buy |
View All
Artivion Inc Stock (AORT) Latest News
Artivion Inc (AORT) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Artivion Q4 Earnings Call Highlights - Yahoo Finance
Artivion Q4 2025 slides: double-digit growth across product lines, strong 2026 outlook By Investing.com - Investing.com South Africa
Artivion (AORT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Artivion Q4 2025 slides: double-digit growth across product lines, strong 2026 outlook - Investing.com India
Earnings call transcript: Artivion Q4 2025 beats EPS forecast, stock rises - Investing.com
Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations - Finviz
Artivion (AORT) Q4 Earnings Surpass Estimates - Yahoo Finance UK
Artivion: Fourth Quarter Financial Highlights - Bitget
Artivion: Q4 Earnings Snapshot | State | mdjonline.com - Marietta Daily Journal
Artivion: Q4 Earnings Snapshot - kare11.com
Artivion (NYSE:AORT) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Earnings Flash (AORT) Artivion, Inc. Reports Q4 Revenue $116.0M, vs. FactSet Est of $116.5M - marketscreener.com
Artivion shares fall as Q4 revenue misses analyst estimates By Investing.com - Investing.com Australia
Artivion shares fall as Q4 revenue misses analyst estimates - Investing.com
Artivion Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire
MACD Signal: Will Artivion Inc stock go up in YEARWatch List & Low Drawdown Momentum Ideas - baoquankhu1.vn
Artivion earnings on deck: Can revenue growth offset profit concerns? By Investing.com - Investing.com Nigeria
Artivion earnings on deck: Can revenue growth offset profit concerns? - Investing.com
Artivion Becomes Oversold (AORT) - Nasdaq
Aug Wrap: Is Artivion Inc stock undervalued right nowSwing Trade & Real-Time Buy Zone Alerts - baoquankhu1.vn
What To Expect From Artivion's (AORT) Q4 Earnings - Finviz
What To Expect From Artivion’s (AORT) Q4 Earnings - TradingView
Is PDF Solutions Inc subject to activist investor interest2025 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn
Market Recap: Is Artivion Inc stock undervalued right now2025 Technical Patterns & Technical Pattern Alert System - baoquankhu1.vn
Artivion, Inc. (NYSE:AORT) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
US Market Recap: Whats the beta of Artivion Inc stockTake Profit & AI Driven Stock Price Forecasts - baoquankhu1.vn
Artivion (AORT) to Release Earnings on Thursday - Defense World
Earnings Miss: Is Artivion Inc a momentum stockJuly 2025 Short Interest & AI Driven Price Predictions - baoquankhu1.vn
Aug Outlook: What is the long term forecast for Artivion Inc stock2025 Fundamental Recap & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Sell Signal: Is Artivion Inc being accumulated by smart moneyJuly 2025 Momentum & Low Risk Growth Stock Ideas - baoquankhu1.vn
Artivion, Inc. (AORT) Investor Outlook: Potential Upside Of 25.43% And Strong Buy Ratings - DirectorsTalk Interviews
Artivion reports positive clinical data from aortic arch trials By Investing.com - Investing.com Nigeria
The Analyst Verdict: Artivion In The Eyes Of 4 Experts - Benzinga
Needham Reiterates Buy Rating for Artivion (AORT) with $58 Targe - GuruFocus
Artivion (NYSE:AORT) Receives Buy Rating from Needham & Company LLC - MarketBeat
Artivion, Inc. Announces Presentation of Positive New Clinical Data from Endospan's Nexus Trial and its Amds PERSEVERE IDE Trial - marketscreener.com
Artivion (AORT) Unveils Promising Clinical Data from Key Trials - GuruFocus
Artivion reports positive clinical data from aortic arch trials - Investing.com
Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting - PR Newswire
Artivion (AORT) Valuation Check After Recent Share Price Moves And Growth Outlook - Yahoo Finance UK
Market Outlook: Whats next for Artivion Inc stockWeekly Trade Analysis & Low Risk Investment Opportunities - baoquankhu1.vn
What is the long term forecast for Artivion Inc. stockWeekly Profit Summary & Free Community Consensus Stock Picks - mfd.ru
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results - ChartMill
Aug Sentiment: Is Artivion Inc a momentum stockJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - baoquankhu1.vn
Aug Decliners: Is Artivion Inc stock undervalued right now2025 Market Outlook & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Artivion (NYSE:AORT) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
Artivion, Inc. (AORT) Stock Analysis: Unlocking a Potential 19% Upside in the Medical Devices Sector - DirectorsTalk Interviews
Are Options Traders Betting on a Big Move in Artivion Stock? - MSN
Relative Strength Alert For Artivion - Nasdaq
Artivion, Inc. (AORT) Stock Analysis: 20% Upside Potential and a Strong Buy Consensus Signal Opportunity for Investors - DirectorsTalk Interviews
Artivion Inc Stock (AORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):